BTK inhibition has proven to be a highly successful therapeutic target in management of various B-cell malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma [182,183]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.